Recurrent Colorectal Carcinoma, Thrombopenia
Conditions
Keywords
Recombinant human interleukin-11, Recombinant human thrombopoietin
Brief summary
This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia.
Detailed description
Most patients with recurrent CRC have undergone a six-month postoperative adjuvant chemotherapy with oxaliplatin plus fluorouracil. Although the main dose-limiting side effect of oxaliplatin is neurotoxicity, with the widespread use of this drug, there are more and more reports that oxaliplatin is discontinued because of thrombocytopenia, which increases the risk of bleeding, rate of blood transfusion needs and length of stay. On the other hand, patients undergoing pelvic radiotherapy may also experience significant bone marrow suppression because flat bones such as the tibia may be exposed to high doses radiation. Low platelet counts is an urgent problem to be solved in order to give adequate quantitative radiotherapy. This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia, thus providing more evidence in clinical practice.
Interventions
DRUGrhIL-11
rhIL-11 50ug/kg, subcutaneous injection, qd
RADIATIONradiotherapy
in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
DRUGrhTPO
rhTPO 300u/kg, subcutaneous injection, qd
DRUGirinotecan
80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
DRUGRaltitrexed
3mg/m2 q3w
Sponsors
Fudan University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The primary tumor is colorectal cancer, histologically proved recurrence or metastasis disease, or pelvic relapse within 6 months after oxaliplatin-based adjuvant chemotherapy. * Not suitable for re-use of oxaliplatin and fluorouracil. * No medication history of irinotecan. * Lesions evaluable, and has indications for radiotherapy. * UGT1A1\*28 gene phenotype is 6/6 or 6/7 * Karnofsky physical condition score ≥ 70 * Baseline platelet counts are 25-75×10\^9/L, other bone marrow reserve and liver and kidney function meet the requirements of radiotherapy * Able to follow the program during the study period * Sign the informed consent
Exclusion criteria
* Pregnant or breastfeeding women * Those with other history of malignant disease in the past 5 years, except for cured skin cancer and cervical carcinoma in situ * If there is an uncontrolled history of epilepsy, central nervous system disease or mental disorder, the investigator may determine that the clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance. * Clinically severe (ie, active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring medication intervention (see appendix 12), or a history of myocardial infarction in the last 12 months * Organ transplantation requires immunosuppressive therapy * Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant diseases * Subject blood routine and biochemical indicators do not meet the following criteria: hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; Alanine transaminase (ALT), aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal; alkaline phosphatase (ALP) ≤2.5 times the normal upper limit; serum total bilirubin \<1.5 times the normal upper limit; serum creatinine \<1 times the normal upper limit; serum albumin ≥ 30g / L * Anyone who is allergic to any research medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of recovery of platelet accounts | From date of chemoradiation until the date of first documented recovery, assessed up to 6 months |
| the duration after returning to normal | From date of first documented recovery until the date of first documented decrease of platelet accounts, assessed up to 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cycles of concurrent chemotherapy patients received during radiotherapy | through chemoradiation, an average of 5 weeks | — |
| change of participant quality of life during treatment as assessed by EORTC-quality of life questionnaire-C30 | at the beginning and the end of chemoradiation. | — |
| change of participant quality of life during treatment as assessed by EuroQol-5 dimensional (EQ-5D) questionnaire | at the beginning and the end of chemoradiation. | — |
| the rate of pathological complete response. | Surgery scheduled 6-8 weeks after the end of chemoradiation | pathological complete response (pCR) was defined no viable cancer cell under the examination of surgical resection specimen. |
Contacts
Primary ContactJi Zhu, MD
Outcome results
None listed